Here are some of our experts' favorite gene editing plays for the long run.
News & Analysis: CRISPR Therapeutics
Unfortunately, this isn't an endorsement by a big drug developer.
Some of our experts think this stock has tons of long-term potential.
Be realistic about the chances of success, understand the conditions that could create that success, and then act accordingly.
Dogecoin may be breaking its all-time highs every other day, but there's nothing averting a catastrophic fall.
One company is setting itself apart in a crowded field.
Both of these stocks have struggled in recent weeks, which means it might be a good time to initiate a position.
The amended collaboration agreement comes with a big up-front payment.
These companies may represent the future, but their stocks are getting pummeled in the present.
It's a firm maybe.